The Limits of Lifestyle: Why Healthy Habits Alone May Not Protect Your Retirement Years

American life expectancy has stalled at a troubling crossroads. After peaking at 78.8 years in 2019, the rate plummeted during the pandemic and has only partially recovered to 78.4 years in 2023, placing the United States in a dismal 49th globally, with projections showing a further decline to 66th place by 2050. This decline represents not just a temporary setback but a fundamental reversal of decades of progress, leaving the U.S. lagging behind peer nations despite spending more on healthcare than any other country. For Americans who pay into Social Security for 40+ years, this shrinking lifespan means fewer years to reclaim what they’ve invested—a cruel erosion of the retirement promise.

More alarming still is the quality of those years: The US presented the most enormous healthspan-lifespan gap, amounting to 12.4 years, meaning the average American spends their final dozen years battling disease and disability. According to WHO estimates, Americans have a healthspan of only 66.1 years, barely past the Social Security eligibility age of 67, meaning that after decades of contributions, most Americans have precious little healthy time to actually enjoy their benefits.

But true retirement vitality goes beyond merely avoiding disease. The “Big Five” pillars of a vibrant, resilient retirement—cognitive fitness to stay sharp and engaged, strength and mobility to maintain independence, balance and coordination to prevent devastating falls, freedom from chronic pain that saps joy from daily activities, and social connection to nourish the soul—are increasingly out of reach for aging Americans. These aren’t luxury aspirations but fundamental requirements for a retirement worth having. Yet our current approach to aging fails to deliver on these essential elements, leaving millions facing a retirement marked more by limitation than liberation.

This widening chasm between living longer and living well represents a fundamental failure of our approach to aging, where the golden years we’ve saved for become tarnished by illness and incapacity. While diet, exercise, and sleep form the foundation of health, they operate within the constraints of our biological aging process. Even with perfect lifestyle habits, cellular damage accumulates, DNA repair mechanisms fail, and tissues progressively lose function. This biological reality explains why lifestyle interventions alone, though beneficial, cannot close the healthspan-lifespan gap—they can only modestly slow a process that requires more fundamental intervention at the molecular level to restore both the years and the vitality Americans have earned through a lifetime of work.

The Cellular Reality of Aging

Even the most disciplined healthy lifestyle cannot fully address what happens at the cellular level as we age. Key aging processes include:

• Telomere shortening: The protective caps on chromosomes gradually erode with each cell division
• Mitochondrial dysfunction: Our cellular powerhouses become less efficient at producing energy
• Cellular senescence: Damaged cells accumulate but refuse to die, secreting inflammatory compounds
• Epigenetic drift: Gene expression patterns become dysregulated over time
• Protein aggregation: Misfolded proteins accumulate, contributing to neurodegenerative diseases

These processes continue regardless of how many vegetables you eat or miles you run. While healthy habits can slow their progression, they cannot reverse the fundamental molecular damage that accumulates over decades.

Diminishing Returns: When Your Body Stops Responding

One of aging’s cruelest tricks is reducing your body’s ability to benefit from the very behaviors that keep it healthy. This manifests as:

• Metabolic inflexibility: Young bodies efficiently switch between burning carbs and fats. Aging cells lose this adaptability, making it harder to maintain a healthy weight and blood sugar levels, even with optimal nutrition.
• Anabolic resistance: Muscle protein synthesis declines with age. A 70-year-old needs significantly more protein and resistance training to maintain muscle mass compared to a 30-year-old doing the same workout.
• Reduced exercise adaptation: The same training stimulus produces fewer improvements in cardiovascular fitness, strength, and endurance as we age. VO2 max naturally declines about 10% per decade after age 30, even in trained athletes.
• Sleep architecture changes: Deep sleep naturally decreases with age, reducing the restorative benefits even when you maintain good sleep hygiene. Growth hormone secretion during sleep also declines.

The Late Starter’s Dilemma: When Lifestyle Change Comes Too Late

The urgency for pharmaceutical and nutraceutical interventions becomes even more critical for those who wait until after the age of 36 to adopt healthy habits. Recent longitudinal research spanning over 30 years reveals a harsh truth: the temporal accumulation of risky health behaviors creates compound damage that lifestyle changes alone cannot undo.

The Critical Window You’ve Already Missed

If you’re reading this past your mid-30s without a consistent history of healthy living, you face an uphill battle that diet and exercise alone cannot win:

• Accumulated cellular debt: Every year of smoking, heavy drinking, or physical inactivity doesn’t just affect that year—it compounds into what researchers call “temporal risk accumulation.” A 50-year-old who starts exercising faces not just the current effects of aging, but also the accumulated damage from decades of cellular assault.
• Lost protective years: The study found that health behaviors in early adulthood (age 27-36) significantly impact mental well-being and metabolic health decades later. Missing this window means forfeiting crucial years when your body was most responsive to positive inputs.
• The consistency gap: Sporadic attempts at healthy living—the typical pattern of New Year’s resolutions and summer fitness kicks—provide minimal protection. The research shows it’s the continuous, decade-spanning adherence that builds resilience against aging. Without this foundation, you’re essentially starting from a deficit.

Why Pharmaceuticals Become Essential for Late Starters

For those beginning their health journey after 36, targeted interventions transition from “nice to have” to “absolutely necessary”:

• Accelerated cellular repair: While a 25-year-old’s body eagerly responds to exercise-induced autophagy, a 45-year-old late starter needs rapamycin’s potent mTOR inhibition to achieve comparable cellular cleanup.
• Metabolic rescue: Decades of poor diet create metabolic inflexibility that won’t resolve with salads alone. Metformin and acarbose become essential to restore insulin sensitivity that years of abuse have destroyed.
• Inflammation override: The study particularly highlighted how alcohol and smoking create lasting inflammatory patterns. Late starters need LDN, telmisartan, and other anti-inflammatory interventions to break these entrenched patterns.
• Mitochondrial resurrection: After age 36, mitochondrial dysfunction accelerates. Without the protective buffer of early healthy habits, interventions like niclosamide ethanolamine and tadalafil become crucial for restoring cellular energy production.
• Rapid muscle preservation: The research revealed that prolonged periods of physical inactivity have a significant impact on metabolic health. Late starters can’t afford the slow buildup of exercise adaptation—HMB + Vitamin D3 provides a pharmaceutical bridge to maintain function while building fitness.

The Cruel Mathematics of Delayed Action

Consider this sobering calculation: Someone who maintained healthy habits from age 27-50 accumulates 23 years of cellular protection. Someone starting at 40 trying to achieve the same health at 50 has only 10 years, less than half the time to reverse more than double the damage. This mathematical impossibility demands pharmaceutical amplification.

The Finnish data showed that each risky behavior maintained over time increased depression risk by 0.38 points, decreased psychological well-being by 0.15 points, and added 1.49 metabolic risk factors. These aren’t just numbers—they represent stolen years of vitality that lifestyle alone cannot reclaim.

A Pragmatic Protocol for Late Starters

If you’re beginning your health journey after 36, consider this enhanced approach:

• Foundation Phase (months 1-3): Start lifestyle changes while immediately incorporating metformin, vitamin D3, and omega-3s to begin metabolic repair
• Acceleration Phase (months 4-9): Add targeted interventions like acarbose, HMB, and microdosed resveratrol + copper to address accumulated damage
• Optimization Phase (months 10+): Consider advanced interventions like low-dose rapamycin or niclosamide under medical supervision

The message is clear: while it’s never too late to start, starting late means you cannot rely on lifestyle alone. The pharmaceutical tools discussed aren’t optional enhancements for late starters—they’re essential components of any realistic plan to reclaim the healthy retirement years that early neglect has jeopardized.

Molecular Pathways: The Targets Lifestyle Can’t Reach

• Longevity protocols aim to activate or modulate specific molecular pathways that regulate aging:
• mTOR (mechanistic target of rapamycin): This nutrient-sensing pathway regulates cell growth and autophagy. While caloric restriction partially inhibits mTOR, targeted interventions may achieve more precise modulation.
• Sirtuins: These proteins regulate cellular health, DNA repair, and metabolism. While exercise and fasting modestly boost sirtuin activity, targeted approaches may further amplify these effects.
• AMPK (AMP-activated protein kinase): This cellular energy sensor promotes mitochondrial biogenesis and fat burning. Exercise activates AMPK, but aging reduces this response.
• NAD+ levels: This crucial coenzyme declines by up to 50% between ages 40 and 60, affecting hundreds of enzymatic reactions. Lifestyle alone cannot restore youthful NAD+ levels.
• Cellular senescence pathways: Emerging senolytic approaches specifically target and remove senescent cells, something no amount of healthy living can achieve directly.

Pharmaceutical and Nutraceutical Interventions: Targeting What Lifestyle Cannot

Several medications originally developed for other conditions, as well as select natural compounds, show promise in targeting fundamental aging mechanisms:

Metformin: The Metabolic Optimizer

Initially a diabetes medication, metformin activates AMP-activated protein kinase (AMPK; your cells’ fuel gauge) and inhibits complex I of the mitochondrial electron transport chain. This creates a mild metabolic stress that:

• Enhances insulin sensitivity beyond what diet alone achieves
• Reduces inflammatory markers like IL-6 and TNF-alpha
• May inhibit the formation of advanced glycation end products (AGEs)
• Potentially reduces cancer incidence through effects on cellular metabolism

While exercise also activates AMPK, metformin provides sustained activation that complements physical activity, particularly as the aging body becomes less responsive to exercise-induced AMPK activation.

Acarbose: Glycemic Control Beyond Diet

This alpha-glucosidase inhibitor slows carbohydrate absorption in the gut, creating effects that even the strictest low-carb diet cannot replicate:

• Reduces post-meal glucose spikes without eliminating carbohydrates entirely
• May extend lifespan through caloric restriction mimetic effects
• Modulates the gut microbiome in ways that promote metabolic health
• Reduces AGE formation by limiting glucose availability

Rapamycin: The mTOR Master Switch

Perhaps the most potent longevity intervention, rapamycin directly inhibits mTOR, achieving what no amount of fasting or caloric restriction can fully accomplish:

• Enhances autophagy to levels beyond what lifestyle interventions achieve
• Improves immune function paradoxically through immunomodulation
• Preserves stem cell function and regenerative capacity
• May prevent age-related diseases across multiple organ systems

While intermittent fasting partially inhibits mTOR, rapamycin’s targeted approach can achieve more complete and sustained inhibition when dosed appropriately.

Fisetin: The Senolytic Cell Purge

Among the most promising interventions for addressing cellular aging is fisetin, a natural flavonoid that acts as a potent senolytic. This compound selectively eliminates senescent “zombie” cells that accumulate with age:

• Targeted senescent cell removal: Unlike any lifestyle intervention, fisetin specifically identifies and triggers apoptosis in senescent cells while leaving healthy cells untouched. These dysfunctional cells, which refuse to die and secrete inflammatory compounds (SASP factors), cannot be removed through diet or exercise alone.
• Inflammation cascade interruption: By eliminating senescent cells, fisetin addresses a root cause of inflammaging—the chronic, low-grade inflammation that drives multiple age-related diseases. Studies show reductions in IL-6, TNF-α, and other inflammatory markers that persist despite healthy lifestyle habits.
• Tissue regeneration enablement: Removing senescent cells creates space and reduces inflammatory signals, allowing stem cells and healthy cells to function more effectively. This regenerative potential exceeds what any amount of healthy living can achieve in aging tissues.
• Multi-organ benefits: Research demonstrates fisetin’s effects across multiple organ systems—improving kidney function, reducing cardiac fibrosis, enhancing liver metabolism, and potentially improving cognitive function by clearing senescent cells from the brain.
• Periodic dosing advantage: Unlike daily medications, fisetin is typically used in periodic high-dose “hit and run” protocols, minimizing side effects while achieving sustained benefits through senescent cell clearance.

The accumulation of senescent cells is an inevitable consequence of aging that no amount of vegetables, exercise, or meditation can prevent. While healthy habits may slow their accumulation, only targeted senolytic interventions, such as fisetin, can actively remove these cellular troublemakers, offering a regenerative reset that lifestyle changes alone cannot provide. This makes fisetin particularly valuable for those seeking to address the cellular debris accumulated over decades of living, regardless of the healthiness of those decades.

Microdosed Resveratrol + Copper: The Cell-Free Chromatin Deactivator

A groundbreaking approach involves the surprising combination of low-dose resveratrol with trace amounts of copper. While resveratrol is widely known as an antioxidant, when combined with copper in specific ratios (1:10,000), it becomes a pro-oxidant that generates targeted oxygen radicals:

• Deactivates cell-free chromatin particles (cfChPs) – DNA fragments released from the billions of cells that die daily in our bodies
• Addresses a root cause of aging – these cfChPs enter healthy cells, damaging mitochondrial DNA, and triggering inflammation
• Uses remarkably low doses – 1 mg/kg resveratrol with just 0.1 μg/kg copper, far below typical supplement doses
• Shown to reverse multiple aging markers in studies, including telomere attrition, amyloid deposition, DNA damage, and mitochondrial dysfunction

This mechanism is particularly compelling because it targets an upstream cause of aging rather than just symptoms. With 10⁹-10¹² cells dying in the body daily, the continuous assault by cfChPs represents a previously unrecognized driver of aging that lifestyle alone cannot address.

Niclosamide Ethanolamine: The Mitochondrial Enhancer

Originally an antiparasitic, niclosamide ethanolamine uncouples mitochondria in a controlled manner:

• Stimulates mitochondrial biogenesis beyond exercise-induced levels
• Activates AMPK through energy depletion signaling
• May clear damaged mitochondria through enhanced mitophagy
• Potentially reduces cellular senescence burden

This creates a metabolic state similar to exercise but targets mitochondria more specifically than physical activity alone.

Low-Dose Naltrexone (LDN): Immune System Rebalancing

At low doses, naltrexone modulates the immune system in ways that address inflammaging:

• Temporarily blocks opioid receptors, triggering increased endorphin production and compensatory opioid growth factor expression
• Reduces inflammatory cytokines that accumulate with age by blocking TLR4 receptors on immune cells, directly inhibiting IL-6 and other inflammatory markers
• May enhance regulatory T cell function and modulate microglial activation in the brain
• Demonstrated 16.7% improvement in immune function scores in recent clinical data
• Enables medication discontinuation: 23.8% of users stopped other drugs, particularly anti-inflammatories and pain medications

This immune rebalancing cannot be achieved solely through lifestyle interventions, as it targets specific receptor systems that diet and exercise cannot directly modulate.

Tadalafil: Vascular and Mitochondrial Protection

Beyond its known effects on erectile function, this PDE5 inhibitor offers systemic benefits:

• Improves endothelial function throughout the vascular system
• Enhances mitochondrial biogenesis in multiple tissues
• Reduces inflammation and oxidative stress
• May improve cognitive function through increased cerebral blood flow

While exercise improves vascular function, tadalafil provides sustained activation of the nitric oxide pathway, which aging bodies struggle to maintain naturally.

Telmisartan: The Multi-Modal Angiotensin Receptor Blocker (ARB)

This angiotensin receptor blocker goes beyond blood pressure control:

• Acts as a partial PPAR-gamma agonist, improving metabolic health
• Enhances mitochondrial function and biogenesis
• Reduces inflammation through multiple pathways
• May improve cognitive function and reduce Alzheimer’s risk

These metabolic effects exceed what lifestyle modifications alone can achieve, particularly in aging individuals with declining receptor sensitivity.

HMB + Vitamin D3: The Muscle Function Preservers

Recent long-term research demonstrates that calcium β-hydroxy-β-methylbutyrate (HMB) combined with vitamin D3 offers unique benefits for aging muscle:

• Preserves functional capacity even without exercise training
• Improves composite functional index (handgrip, Get Up, Get Up and Go tests)
• Maintains knee extension strength that typically declines with age
• Increases lean body mass when vitamin D levels are sufficient
• Requires vitamin D sufficiency (>30 ng/mL) for optimal HMB effectiveness

A 12-month study showed that 3g/day of HMB, combined with 2,000 IU/day of vitamin D3, helped non-exercising older adults maintain functional abilities comparable to those achieved through resistance training. This is particularly valuable for the substantial population that is unable or unwilling to exercise regularly, offering a pharmaceutical bridge to preserve muscle function that lifestyle alone cannot maintain in the aging process.

Simvastatin: The Multi-Modal Longevity Activator

Originally developed as a cholesterol-lowering drug, this fat-soluble statin triggers multiple anti-aging processes that healthy habits alone cannot achieve:

• Activates cellular cleanup mechanisms: While fasting temporarily boosts autophagy (your body’s recycling system), simvastatin keeps this cleanup process running more consistently, helping aged cells clear out damaged components they would otherwise accumulate
• Quiets inflammatory “zombie” cells: Instead of killing senescent cells like some drugs do, simvastatin significantly reduces their toxic inflammatory signals—particularly IL-6 and IL-8—essentially muting their harmful chatter without eliminating them
• Protects the aging brain: Unlike water-soluble medications that can’t enter the brain, simvastatin crosses the blood-brain barrier where it reduces brain inflammation, strengthens connections between neurons, and substantially cuts dementia risk with long-term use
• Rebalances the immune system: Converts inflammatory immune cells into healing ones while boosting the regulatory cells that prevent autoimmune damage—a level of immune restoration that no amount of healthy eating or exercise can match
• Enhances cellular energy sensing: Works alongside metformin to activate AMPK through different pathways, providing complementary metabolic benefits while potentially reducing muscle side effects when used together

Real-world evidence shows modest but meaningful lifespan extension, and more importantly, compression of illness into a shorter period, resulting in more healthy years before decline. The remarkable finding is that anti-aging benefits occur at lower doses than those used for aggressive cholesterol control, reducing side effects while maintaining benefits. With generic versions costing less than many monthly supplements, simvastatin offers one of the most affordable ways to target multiple aging mechanisms that lifestyle alone cannot address.

The Synergy Solution: Combining Approaches

The most promising strategy combines foundational lifestyle benefits with targeted pharmaceutical and nutraceutical interventions:

• The most promising strategy combines foundational lifestyle benefits with targeted pharmaceutical and nutraceutical interventions:
• Enhanced cellular repair: While exercise stimulates autophagy, combining it with rapamycin may amplify cellular cleanup to levels impossible through lifestyle alone.
• Metabolic optimization: Dietary improvements work synergistically with metformin and acarbose to achieve glycemic control that neither approach could accomplish independently.
• Vascular health: Exercise-induced vascular benefits are enhanced by tadalafil’s sustained nitric oxide support, vital as NO production declines with age.
• Inflammation control: Anti-inflammatory lifestyle habits combined with LDN create complementary pathways. Recent data show that 69.2% of LDN users experience significant health improvements, with nearly a quarter discontinuing other medications entirely, demonstrating how targeted interventions can amplify lifestyle benefits.
• Mitochondrial support: Exercise-induced mitochondrial biogenesis is amplified by niclosamide ethanolamine, metformin, and tadalafil, creating a multi-pronged approach to cellular energy production.
• Muscle preservation: HMB + vitamin D3 maintains functional capacity in those unable to exercise, while enhancing vitamin D status enables other interventions to work optimally, creating a foundation for sustained physical independence.
• Cellular protection: The microdosed resveratrol + copper combination uniquely addresses the upstream cause of cellular damage from cfChPs, providing a foundation that enhances the effectiveness of all other interventions.
• Senescent cell clearance: Fisetin’s periodic senolytic purges remove the inflammatory “zombie” cells that accumulate despite healthy habits. This cellular housecleaning synergizes powerfully with other interventions—cleared tissues respond better to metformin’s metabolic optimization, rapamycin’s autophagy enhancement works more efficiently without senescent cell interference, and the reduced inflammatory burden amplifies the effects of LDN and lifestyle modifications. The removal of SASP-secreting cells creates a cleaner cellular environment, allowing all other interventions to function optimally.
• Multi-modal longevity activation: Low-dose simvastatin triggers multiple anti-aging processes through pathways distinct from other interventions. It quiets the inflammatory signals from senescent cells that fisetin doesn’t eliminate. At the same time, its brain-protective properties cross the blood-brain barrier to provide neuroprotection that other systemic drugs cannot achieve. By rebalancing immune cells from an inflammatory to a healing state and maintaining consistent cellular cleanup mechanisms, simvastatin amplifies the benefits of exercise and dietary improvements, making it a cornerstone of comprehensive anti-aging protocols.

Precision and Personalization

These pharmaceutical and nutraceutical tools allow for:

• Targeted intervention based on individual aging patterns and biomarkers
• Dose optimization to achieve benefits while minimizing side effects
• Cycling strategies that prevent adaptation and maintain effectiveness
• Combination approaches that address multiple aging pathways simultaneously

The Future of Healthy Aging

The goal isn’t to replace healthy lifestyle habits but to reclaim the promise of retirement that Americans have earned through decades of work. With life expectancy stalling at 78.4 years and healthspan ending at 66.1, we face a brutal reality. After paying into Social Security for 40+ years, most Americans get barely a year of healthy retirement before chronic disease takes hold. This isn’t just a personal tragedy—it’s a societal failure that demands a new approach.

The integrated strategy requires:

• Closing the 12.4-year gap: Rather than accepting that our final dozen years will be marked by disability and disease, we must utilize every available tool—lifestyle optimization combined with targeted pharmaceuticals—to compress morbidity and extend healthspan toward lifespan.
• Restoring the retirement promise: Americans deserve to enjoy the benefits they’ve paid for. By targeting the molecular mechanisms of aging, we can help ensure that reaching Social Security eligibility at 67 marks the beginning of vibrant years, not the onset of decline.
• Reversing our global decline: As the U.S. slides from 49th to a projected 66th place in life expectancy, we need interventions that go beyond incremental improvements. The combination of lifestyle foundations with pharmaceutical amplifiers offers hope for reversing this trajectory.

This isn’t about chasing immortality—it’s about justice. Every American who has contributed to society deserves to reap the rewards of their labor in good health. By embracing both time-tested lifestyle wisdom and cutting-edge molecular interventions, we may be able to transform the current cruel arithmetic of aging into a more equitable equation where the golden years we’ve saved for truly shine.

References:

1. Alasadi A, Chen M, Swapna GVT, et al. Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer. Cell Death Dis. 2018;9(2):215.
2. Anisimov VN, Berstein LM, Popovich IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY). 2011;3(2):148-57.
3. Aversa A, Greco E, Bruzziches R, et al. Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization. Endocrine. 2017;56(3):639-648.
4. Babcook MA, et al. Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer. Mol Cancer Ther. 2014 Oct;13(10):2288-302.
5. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43(5):993-1002.
6. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY). 2019;11(19):8048-8067.
7. Crimmins EM. Lifespan and Healthspan: Past, Present, and Promise. Gerontologist. 2015;55(6):901-11.
8. Fassbender K, et al. Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5856-61.
9. Garmany A, Terzic A. Global Healthspan-Lifespan Gaps Among 183 World Health Organization Member States. JAMA Netw Open. 2024;7(12):e2448995.
10. Giannetta E, Isidori AM, Galea N, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012;125(19):2323-33.
11. Grynkiewicz G, Demchuk OM. New Perspectives for Fisetin. Front Chem. 2019 Oct 30;7:697
12. Harinath G, Nyquist A, Wouters M, et al. Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics. Aging Biol. 2024.
13. Harrison DE, Strong R, Alavez S, et al. Acarbose improves health and lifespan in aging HET3 mice. Aging Cell. 2019;18(2):e12898.
14. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-5.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22.
16. Hsueh W, Davidai G, Henry R, Mudaliar S. Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J Clin Hypertens (Greenwich). 2010 Sep;12(9):746-52.
17. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338-45.
18. Kekäläinen T, Ahola J, Reinilä E, Savikangas T, Kinnunen ML, Pitkänen T, Kokko K. Cumulative associations between health behaviours, mental well-being, and health over 30 years. Ann Med. 2025;57(1):2479233.
19. Koka S, Xi L, Kukreja RC. Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling. Am J Physiol Heart Circ Physiol. 2014;306(11):H1558-68.
20. Kulkarni AS, Gubbi S, Barzilai N. Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metab. 2020;32(1):15-30.
21. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 2013;123(3):980-9.
22. Liu X, et al. Simvastatin suppresses breast cancer cell proliferation induced by senescent cells. Sci Rep. 2015 Dec 14;5:17895.
23. Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett. 2014;349(1):8-14.
24. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-217.
25. Maejima Y, Okada H, Haraguchi G, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest. 2011;91(6):932-44.
26. Martens CR, Rossman MJ, Mazzo MR, Jankowski LR, Nagy EE, Denman BA, et al. Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Ageing Res Rev. 2024 Sep;100:102419.
27. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192.
28. Miller RA, Harrison DE, Allison DB, et al. Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice. Aging Cell. 2022;21(11):e13731.
29. Olmastroni E, et al. Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022 May 6;29(5):804-814.
30. Onken B, Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One. 2010;5(1):e8758.
31. Pal K, Raghuram GV, Dsouza J, Shinde S, Jadhav V, Shaikh A, Rane B, Tandel H, Kondhalkar D, Chaudhary S, Mittra I. A pro-oxidant combination of resveratrol and copper down-regulates multiple biological hallmarks of ageing and neurodegeneration in mice. Sci Rep. 2022 Oct 14;12(1):17209.
32. Patten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn’s Disease, and Other Chronic Pain Disorders. Pharmacotherapy. 2018;38(3):382-389.
33. Pesterfield LL, et al. Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation. PLoS One. 2012;7(6):e39581.
34. Raghuram GV, Chaudhary S, Johari S, Mittra I. Illegitimate and Repeated Genomic Integration of Cell-Free Chromatin in the Aetiology of Somatic Mosaicism, Ageing, Chronic Diseases and Cancer. Genes (Basel). 2019 May 28;10(6):407.
35. Raghuram GV, Tripathy B, Avadhani BK, Shabrish S, Khare NK, Lopes R, Pal K, Mittra I. Cell-free chromatin particles released from dying cells inflict mitochondrial damage and ROS production in living cells. bioRxiv 2021.12.30.47452.
36. Rathmacher JA, Pitchford LM, Khoo P, Angus H, Lang J, Lowry K, Ruby C, Krajek AC, Fuller JC, Sharp RL. Long-term Effects of Calcium β-Hydroxy-β-Methylbutyrate and Vitamin D3 Supplementation on Muscular Function in Older Adults With and Without Resistance Training: A Randomized, Double-blind, Controlled Study. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2089-2097.
37. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9.
38. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109(17):2054-7.
39. Smith BJ, Miller RA, Ericsson AC, Harrison DC, Strong R, Schmidt TM. Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice. BMC Microbiol. 2019;19(1):130.
40. Strong R, Miller RA, Antebi A, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2016;15(5):872-84.
41. Sun N, Youle RJ, Finkel T. The Mitochondrial Basis of Aging. Mol Cell. 2016;61(5):654-666.
42. Tao H, Zhang Y, Zeng X, Shulman GI, Jin S. Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med. 2014;20(11):1263-9.
43. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82.
44. Wang ST, et al. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017 Feb 23;8(2):e2626.
45. Whitehead NP, et al. Enhanced autophagy as a potential mechanism for the improved physiological function by simvastatin in muscular dystrophy. Autophagy. 2016 Dec;12(12):2489-2490.
46. Wolozin B, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 2007 Jul 19;5:20.
47. Wyld L, Bellantuono I, Tchkonia T, Morgan J, Turner O, Foss F, et al. Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies. Cancers (Basel). 2020 Aug 7;12(8):2134.
48. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-9.
49. Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018 Oct;36:18-28.
50. Zhou J, Massey S, Story D, Li L. Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate delays aging phenotypes in mice. Sci Rep. 2022;12(1):7300.
51. Zhu Y, Doornebal EJ, Pirtskhalava T, Giorgadze N, Wentworth M, Fuhrmann-Stroissnigg H, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017 Mar 8;9(3):955-963.